In particular, imaging of neuroendocrine tumors [1,2] exhibiting overexpression of somatostatin receptor type 2 (SSTR2) was promisingly demonstrated in some clinical and preclinical studies with somatostatine analogues [3,4,5]. This evidence concerns the gene SSTR2 and neuroendocrine neoplasm.